Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma

Recent studies addressing the role of adjuvant chemotherapy in cholangiocarcinoma (CCA) have been published; however, there are challenges in generalizing the findings due to different prognostic characteristics depending on tumor location and resectability. Therefore, the aim of this study was to investigate the role of AC in distal cholangiocarcinoma, a common tumor subtype of CCA.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Distal Cholangiocarcinoma Adjuvant Chemotherapy

Age range

19 year–90 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with distal cholangiocarcinoma who underwent surgery

Exclusion criteria

Who underwent neoadjuvant treatment
Who underwent R2 resection
Non-adenocarcinoma patients in final pathology report
Insufficient data
Death within 90days of surgery

Treatment and study plan

Adjuvant chemotherapy

Drug

Adjuvant chemotherapy with or without radiotherapy

Primary outcomes

Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma

Time frame: From January 2000 to December 2021

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Registry information

Official study title

Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma: a Retrospective Cohort Study

Important dates

Study start: 2000
Primary completion: 2021
Study completion: 2024
First posted: Nov 4, 2024
Registry last updated: Nov 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed